Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs

Transplant Immunology

Volumn 32, Issue 2, 2015, Pages 99-108

  Iwase, H ^a   Ekser, B ^a,b,f   Satyananda, V ^a   Zhou, H ^a,c   Hara, H ^a   Bajona, P ^a   Wijkstrom, M ^a   Bhama, J K ^d   Long, C ^a   Veroux, M ^b   Wang, Y ^c   Dai, Y ^e   Phelps, C ^e   Ayares, D ^e   Ezzelarab, M B ^a   Cooper, D K C ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c THE SECOND AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e REVIVICOR INC   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD40 monoclonal antibody; Artery patch; Costimulation blockade; CTLA4 Ig; Pig; Xenotransplantation

Indexed keywords

ABATACEPT; BELATACEPT; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTERY PATCH TRANSPLANTATION; ARTICLE; BABOON; CELL INFILTRATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MHC CLASS II TRANSACTIVATOR GENE; MUTANT; NONHUMAN; PRIORITY JOURNAL; SWINE; T LYMPHOCYTE; TRANSPLANTATION; ANIMAL; ARTERY; GENETICS; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; ORGAN TRANSPLANTATION; PIG; TRANSGENIC ANIMAL; TRANSPLANTATION TOLERANCE; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARTERIES; GRAFT SURVIVAL; HETEROGRAFTS; HUMANS; NUCLEAR PROTEINS; ORGAN TRANSPLANTATION; PAPIO; SWINE; TRANS-ACTIVATORS; TRANSPLANTATION TOLERANCE;

EID: 84926421257     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2015.02.003     Document Type: Article

References (71)

1. Phelps C.J., Koike C., Vaught T.D., Boone J., Wells K.D., Chen S.H., et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003, 299:411-414. [New York, NY].
2. Kolber-Simonds D., Lai L., Watt S.R., Denaro M., Arn S., Augenstein M.L., et al. Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci U S A 2004, 101:7335-7340.
3. Cooper D.K., Good A.H., Koren E., Oriol R., Malcolm A.J., Ippolito R.M., et al. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1993, 1:198-205.
4. Cooper D.K., Koren E., Oriol R. Genetically engineered pigs. Lancet 1993, 342:682-683.
5. Cozzi E., White D.J. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995, 1:964-966.
6. Loveland B.E., Milland J., Kyriakou P., Thorley B.R., Christiansen D., Lanteri M.B., et al. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons. Xenotransplantation 2004, 11:171-183.
7. Cooper D.K., Dorling A., Pierson R.N., Rees M., Seebach J., Yazer M., et al. Alpha1,3-galactosyltransferase gene-knockout pigs for xenotransplantation: where do we go from here?. Transplantation 2007, 84:1-7.
8. Ekser B., Ezzelarab M., Hara H., van der Windt D.J., Wijkstrom M., Bottino R., et al. Clinical xenotransplantation: the next medical revolution?. Lancet 2012, 379:672-683.
9. Ezzelarab M., Garcia B., Azimzadeh A., Sun H., Lin C.C., Hara H., et al. The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009, 87:805-812.
10. Cooper D.K., Satyananda V., Ekser B., Van der Windt D.J., Hara H., Ezzelarab M., et al. Progress in pig-to-nonhuman primate transplantation models (1998-2013): a comprehensive review of the literature. Xenotransplantation 2014, 21:397-419.
11. Buhler L., Awwad M., Basker M., Gojo S., Watts A., Treter S., et al. High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000, 69:2296-2304.
12. Kuwaki K., Knosalla C., Dor F.J., Gollackner B., Tseng Y.L., Houser S., et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004, 4:363-372.
13. Kuwaki K., Tseng Y.L., Dor F.J., Shimizu A., Houser S.L., Sanderson T.M., et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005, 11:29-31.
14. Tseng Y.L., Kuwaki K., Dor F.J., Shimizu A., Houser S., Hisashi Y., et al. alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6months. Transplantation 2005, 80:1493-1500.
15. Ekser B., Long C., Kumar G., Hara H., Dons E.M., Thacker J., et al. Heart transplantation using genetically-engineered pigs: can CTLA4-lg replace anti-CD154mAb in the immunosuppressive regimen?. Xenotransplantation 2011, 18:284. [Abstract 332].
16. Ezzelarab M.B., Ekser B., Echeverri G., Hara H., Ezzelarab C., Long C., et al. Costimulation blockade in pig artery patch xenotransplantation - a simple model to monitor the adaptive immune response in nonhuman primates. Xenotransplantation 2012, 19:221-232.
17. Phelps C.J., Ball S.F., Vaught T.D., Vance A.M., Mendicino M., Monahan J.A., et al. Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 2009, 16:477-485.
18. Hara H., Witt W., Crossley T., Long C., Isse K., Fan L., et al. Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status. Immunology 2013, 140:39-46.
19. Kenyon N.S., Chatzipetrou M., Masetti M., Ranuncoli A., Oliveira M., Wagner J.L., et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 1999, 96:8132-8137.
20. Kirk A.D., Burkly L.C., Batty D.S., Baumgartner R.E., Berning J.D., Buchanan K., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999, 5:686-693.
21. Wu G., Pfeiffer S., Schroder C., Zhang T., Nguyen B.N., Lea W., et al. Co-stimulation blockade targeting CD154 and CD28/B7 modulates the induced antibody response after a pig-to-baboon cardiac xenograft. Xenotransplantation 2005, 12:197-208.
22. Cardona K., Korbutt G.S., Milas Z., Lyon J., Cano J., Jiang W., et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006, 12:304-306.
23. Hering B.J., Wijkstrom M., Graham M.L., Hardstedt M., Aasheim T.C., Jie T., et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006, 12:301-303.
24. Cardona K., Milas Z., Strobert E., Cano J., Jiang W., Safley S.A., et al. Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 2007, 7:2260-2268.
25. Ford M.L., Larsen C.P. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev 2009, 229:294-306.
26. van der Windt D.J., Bottino R., Casu A., Campanile N., Smetanka C., He J., et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009, 9:2716-2726.
27. Mohiuddin M.M., Corcoran P.C., Singh A.K., Azimzadeh A., Hoyt R.F., Thomas M.L., et al. B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8months. Am J Transplant 2012, 12:763-771.
28. Kawai T., Andrews D., Colvin R.B., Sachs D.H., Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000, 6:114.
29. Kirk A.D., Knechtle S.J., Sollinger H.W. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001, 1(Suppl. 1). [Abstract].
30. Knosalla C., Gollackner B., Cooper D.K. Anti-CD154 monoclonal antibody and thromboembolism revisited. Transplantation 2002, 74:416-417.
31. Knosalla C., Gollackner B., Buhler L., Mueller N.J., Houser S., Mauiyyedi S., et al. Correlation of biochemical and hematological changes with graft failure following pig heart and kidney transplantation in baboons. Am J Transplant 2003, 3:1510-1519.
32. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
33. Pearson T.C., Trambley J., Odom K., Anderson D.C., Cowan S., Bray R., et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002, 74:933-940.
34. Haanstra K.G., Ringers J., Sick E.A., Ramdien-Murli S., Kuhn E.M., Boon L., et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003, 75:637-643.
35. Adams A.B., Shirasugi N., Jones T.R., Durham M.M., Strobert E.A., Cowan S., et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005, 174:542-550.
36. Haanstra K.G., Sick E.A., Ringers J., Wubben J.A., Kuhn E.M., Boon L., et al. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005, 79:1623-1626.
37. Aoyagi T., Yamashita K., Suzuki T., Uno M., Goto R., Taniguchi M., et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant 2009, 9:1732-1741.
38. Thompson P., Cardona K., Russell M., Badell I.R., Shaffer V., Korbutt G., et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant 2011, 11:947-957.
39. Badell I.R., Russell M.C., Cardona K., Shaffer V.O., Turner A.P., Avila J.G., et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am J Transplant 2012, 12:1918-1923.
40. Badell I.R., Thompson P.W., Turner A.P., Russell M.C., Avila J.G., Cano J.A., et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 2012, 12:126-135.
41. Watanabe M., Yamashita K., Suzuki T., Kamachi H., Kuraya D., Koshizuka Y., et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am J Transplant 2013, 13:1976-1988.
42. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326-2333.
43. Larsen C.P., Pearson T.C., Adams A.B., Tso P., Shirasugi N., Strobert E., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5:443-453.
44. Vincenti F., Charpentier B., Vanrenterghem Y., Rostaing L., Bresnahan B., Darji P., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
45. Koshika T., Phelps C., Fang J., Lee S.E., Fujita M., Ayares D., et al. Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules. Immunology 2011, 134:386-397.
46. Martin C., Plat M., Nerriere-Daguin V., Coulon F., Uzbekova S., Venturi E., et al. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic Res 2005, 14:373-384.
47. Phelps C., Vaught T., Ball S., Mendicino M., Walters A., Monahan J., et al. Multi-transgenic pigs designed for xenoislet transplants. Xenotransplantation 2009, 16:374. [Abstract].
48. Leveque X., Cozzi E., Naveilhan P., Neveu I. Intracerebral xenotransplantation: recent findings and perspectives for local immunosuppression. Curr Opin Organ Transplant 2011, 16:190-194.
49. Ayares D., Vaught T., Ball S., Ramsoondar J., Monahan J., Mendicino M., et al. Islet-specific expression of TFPI, CD39, and CTLA4lg in transgenic pigs designed for xenoislet transplantation. Xenotransplantation 2011, 18:269. [Abstract 120].
50. Wijkstrom M., Iwase H., Hara H., Ekser B., der Windt DJ Van, Long C. Glucose metabolism in pigs expressing human genes under an insulin promoter. Xenotransplantation 2015, 22:70-79.
51. Yun S., Gustafsson K., Fabre J.W. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain. Transplantation 1998, 66:103-111.
52. Dai Y., Vaught T.D., Boone J., Chen S.H., Phelps C.J., Ball S., et al. Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002, 20:251-255.
53. Hara H., Long C., Lin Y.J., Tai H.C., Ezzelarab M., Ayares D., et al. In vitro investigation of pig cells for resistance to human antibody-mediated rejection. Transpl Int 2008, 21:1163-1174.
54. Hara H., Koike N., Long C., Piluek J., Roh D.S., SundarRaj N., et al. Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs. Invest Ophthalmol Vis Sci 2011, 52:5278-5286.
55. Cooper D.K., Ye Y., Niekrasz M. Heart transplantation in primates. Handbook of animal models in transplantation research 1994, 173-200. CRC Press, Boca Raton. D.V. Cramer, L.G. Podesta, L. Makowka (Eds.).
56. Lowe M., Badell I.R., Thompson P., Martin B., Leopardi F., Strobert E., et al. A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am J Transplant 2012, 12:2079-2087.
57. Kirk A.D., Harlan D.M., Armstrong N.N., Davis T.A., Dong Y., Gray G.S., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997, 94:8789-8794.
58. Page A., Srinivasan S., Singh K., Russell M., Hamby K., Deane T., et al. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant 2012, 12:115-125.
59. Lowe M.C., Badell I.R., Turner A.P., Thompson P.W., Leopardi F.V., Strobert E.A., et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant 2013, 13:312-319.
60. Yamada K., Yazawa K., Shimizu A., Iwanaga T., Hisashi Y., Nuhn M., et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005, 11:32-34.
61. Griesemer A.D., Hirakata A., Shimizu A., Moran S., Tena A., Iwaki H., et al. Results of gal-knockout porcine thymokidney xenografts. Am J Transplant 2009, 9:2669-2678.
62. Ezzelarab M.B., Zahorchak A.F., Lu L., Morelli A.E., Chalasani G., Demetris A.J., et al. Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant 2013, 13:1989-2005.
63. Lin Y.J., Hara H., Tai H.C., Long C., Tokita D., Yeh P., et al. Suppressive efficacy and proliferative capacity of human regulatory T cells in allogeneic and xenogeneic responses. Transplantation 2008, 86:1452-1462.
64. Chen G., Qian H., Starzl T., Sun H., Garcia B., Wang X., et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005, 11:1295-1298.
65. Shimizu A., Hisashi Y., Kuwaki K., Tseng Y.L., Dor F.J., Houser S.L., et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008, 172:1471-1481.
66. Lee R.S., Yamada K., Womer K.L., Pillsbury E.P., Allison K.S., Marolewski A.E., et al. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses. J Immunol 2000, 164:3434-3444.
67. Mohiuddin M.M., Singh A.K., Corcoran P.C., Hoyt R.F., Thomas M.L., Lewis B.G., et al. One-year heterotopic cardiac xenograft survival in a pig to baboon model. Am J Transplant 2014, 14:488-489.
68. Quinn G., Bower R., Dos-Santos Cruz G., Giovino M., Xu Y., Patience C., et al. Structural and functional characteristics of a dominant-negative isoform of porcine MHC class II transactivator. Eur J Immunogenet 2003, 30:259-270.
69. Qian S., Fu F., Li Y., Lu L., Rao A.S., Starzl T.E., et al. Impact of donor MHC class I or class II antigen deficiency on first- and second-set rejection of mouse heart or liver allografts. Immunology 1996, 88:124-129.
70. Faustman D.L., Steinman R.M., Gebel H.M., Hauptfeld V., Davie J.M., Lacy P.E. Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci U S A 1984, 81:3864-3868.
71. Larsen C.P., Morris P.J., Austyn J.M. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990, 171:307-314.